PELP1-IN-1
Based on 1 Customer Validation
PELP1-IN-1 is a PELP1 inhibitor and an apoptosis inducer with no cytotoxic activity against non-cancer cell lines. PELP1-IN-1 targets wild-type, mutant and drug-resistant ER+ breast cancer, and promotes PELP1 degradation through the proteasome pathway. As an analog of SMIP34 (HY-169903), PELP1-IN-1 is applicable to the research of estrogen receptor α-positive breast cancer.
For research use only. We do not sell to patients.
- Purity : 99.28%
- CAS No.: 946262-80-2
- Formula: C20H15ClFN5O2S
- Molecular Weight:443.88
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
PELP1[1]
In Vitro
PELP1-IN-1 (SM1) (10 μM; 12-48 h) inhibits migration and invasion of ZR75, MCF7 and MT-ER+ breast cancer cells, reduces soft agar colony formation, promotes apoptosis (Annexin V staining, increased caspase 3/7 activity) and induces S-phase cell cycle arrest[1].
PELP1-IN-1 (10 μM; 48 h) downregulates the expression of estrogen response- and cell cycle-related genes, upregulates genes involved in the apoptosis and p53 pathways, and inhibits ER-PELP1 downstream signaling in ZR75 and MCF7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:ZR75, MCF7, MCF7(Y537S), MCF7(D538G), ZR75(Y537S), ZR75(D538G)
-
Concentration:10 μM
-
Incubation Time:24-48 h
-
Result:Induced apoptosis in both WT-ER+ and MT-ER+ breast cancer cells, as indicated by increased Annexin V-positive cells and enhanced caspase 3/7 enzymatic activity.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | MRT0-t | MRT0-∞ | T1/2 | Tmax | CL | Vd | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[2] | 1 mg/kg | i.v. | 970.4 ng·h/mL | 986.7 ng·h/mL | 1.6 h | 1.8 h | 1.3 h | 0.1 h | 1.2 L/h/kg | 2.1 L/kg | 583.4 ng/mL | / |
| Mice[2] | 1 mg/kg | i.v. | 970.4 ng·h/mL | 986.7 ng·h/mL | 1.6 h | 1.8 h | 1.3 h | 0.1 h | 1.2 L/h/kg | 2.1 L/kg | 583.4 ng/mL | / |
| Mice[2] | 1 mg/kg | i.v. | 970.4 ng·h/mL | 986.7 ng·h/mL | 1.6 h | 1.8 h | 1.3 h | 0.1 h | 1.2 L/h/kg | 2.1 L/kg | 583.4 ng/mL | / |
| Mice[2] | 2 mg/kg | p.o. | 1261.6 ng·h/mL | 1419.6 ng·h/mL | 2.1 h | 3.2 h | 2.5 h | 0.8 h | 1.5 L/h/kg | 4.9 L/kg | 614.8 ng/mL | 65.0 % |
| Mice[2] | 2 mg/kg | p.o. | 1261.6 ng·h/mL | 1419.6 ng·h/mL | 2.1 h | 3.2 h | 2.5 h | 0.8 h | 1.5 L/h/kg | 4.9 L/kg | 614.8 ng/mL | 65.0 % |
| Mice[2] | 2 mg/kg | p.o. | 1261.6 ng·h/mL | 1419.6 ng·h/mL | 2.1 h | 3.2 h | 2.5 h | 0.8 h | 1.5 L/h/kg | 4.9 L/kg | 614.8 ng/mL | 65.0 % |
| Mice[2] | 4 mg/kg | p.o. | 3023.6 ng·h/mL | 3050.8 ng·h/mL | 1.6 h | 1.7 h | 1.2 h | 0.8 h | 1.4 L/h/kg | 2.4 L/kg | 1716.6 ng/mL | 77.9 % |
| Mice[2] | 4 mg/kg | p.o. | 3023.6 ng·h/mL | 3050.8 ng·h/mL | 1.6 h | 1.7 h | 1.2 h | 0.8 h | 1.4 L/h/kg | 2.4 L/kg | 1716.6 ng/mL | 77.9 % |
| Mice[2] | 4 mg/kg | p.o. | 3023.6 ng·h/mL | 3050.8 ng·h/mL | 1.6 h | 1.7 h | 1.2 h | 0.8 h | 1.4 L/h/kg | 2.4 L/kg | 1716.6 ng/mL | 77.9 % |
| Mice[2] | 8 mg/kg | p.o. | 6149.6 ng·h/mL | 6208.9 ng·h/mL | 1.6 h | 1.7 h | 1.1 h | 0.8 h | 1.3 L/h/kg | 2.0 L/kg | 3045.6 ng/mL | 79.2 % |
| Mice[2] | 8 mg/kg | p.o. | 6149.6 ng·h/mL | 6208.9 ng·h/mL | 1.6 h | 1.7 h | 1.1 h | 0.8 h | 1.3 L/h/kg | 2.0 L/kg | 3045.6 ng/mL | 79.2 % |
| Mice[2] | 8 mg/kg | p.o. | 6149.6 ng·h/mL | 6208.9 ng·h/mL | 1.6 h | 1.7 h | 1.1 h | 0.8 h | 1.3 L/h/kg | 2.0 L/kg | 3045.6 ng/mL | 79.2 % |
Chemical Information
-
CAS No. 946262-80-2
-
Appearance Solid
-
Molecular Weight 443.88
-
Formula C20H15ClFN5O2S
-
Color White to off-white
-
SMILES
O=C1C2=C(N(C3=CC=C(Cl)C=C3)N=C2)N=C(SCC(NCC4=CC=C(F)C=C4)=O)N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 4.57 mg/mL (10.30 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2529 mL | 11.2643 mL | 22.5286 mL | 56.3215 mL |
| 5 mM | 0.4506 mL | 2.2529 mL | 4.5057 mL | 11.2643 mL | |
| 10 mM | 0.2253 mL | 1.1264 mL | 2.2529 mL | 5.6322 mL |
Keywords
- PELP1-IN-1
- 946262-80-2
- Apoptosis
- Estrogen Receptor/ERR
- mammary epithelial cells
- ovarian epithelial cells
- wild-type ER+ breast cancer
- therapy-resistant ER+ breast cancer
- endometrial epithelial cells
- PELP1
- mutant ER+ breast cancer
- proteasome pathway
- estrogen receptor alpha-positive breast cancers
- Inhibitor
- inhibitor
- inhibit